A marked, persistent reduction in sexual interest, thoughts, initiation, or arousal, present for at least six months and causing real distress.
Medically reviewed by
Dr. Mihaela G.
Female Sexual Interest/Arousal Disorder (FSIAD) combines what earlier diagnostic frameworks treated as two separate conditions, low sexual desire and difficulty becoming aroused, into a single diagnosis, reflecting research showing how closely intertwined desire and arousal actually are for many women, rather than functioning as two clearly distinct, sequential stages. The diagnosis requires a marked reduction or absence in at least three of six specific areas: interest in sexual activity, sexual or erotic thoughts, initiation of sexual activity, excitement or pleasure during activity, response to internal or external erotic cues, and genital or non-genital sensations during sexual activity.
This breadth matters. It means the diagnosis captures genuinely different presentations, a woman who’s lost interest in initiating sex but feels aroused once it begins, and a woman who initiates regularly but struggles to feel physically or mentally engaged once sexual activity starts, both potentially qualify, depending on which combination of the six areas is affected.
A defining and important feature, shared with the other conditions in this chapter, is the requirement for distress. Lower sexual interest that isn’t bothering the person, perhaps it’s simply a stable, comfortable part of who they are, or reflects a mismatch with a partner’s higher desire without personal distress about it, doesn’t meet criteria for a disorder. This distinction matters enormously for avoiding the pathologizing of genuine variation in sexual desire across the population.
Reduced or absent interest in sexual activity
A marked decrease in interest in engaging in sexual activity, distinct from simply being busy or tired occasionally, reflecting a persistent, significant change or longstanding pattern.
Reduced or absent sexual thoughts
A noticeable decrease in erotic or sexual thoughts or fantasies, which for many women previously occurred spontaneously or in response to relevant cues.
Reduced initiation, and reduced receptivity to a partner’s initiation
A marked decrease in initiating sexual activity, and in many cases, reduced responsiveness to a partner’s attempts to initiate.
Reduced excitement or pleasure
Significantly diminished excitement or pleasure during sexual activity on almost all occasions, even when activity does occur.
Reduced arousal in response to cues
Decreased arousal in response to internal or external erotic cues, written, verbal, or visual material that would previously have generated interest or arousal.
Reduced genital or non-genital sensations
Diminished physical sensations during sexual activity, which can include reduced lubrication or other physical arousal responses.
⋅ Distress or concern connected to the reduced interest or arousal
⋅ Worry about the impact on a partner or the relationship
⋅ Diminished sense of sexual self, sometimes affecting broader self-esteem
⋅ Guilt connected to perceived mismatch with a partner’s desire
⋅ Reduced frequency or absence of spontaneous sexual or erotic thoughts
⋅ Diminished responsiveness to erotic cues that previously generated interest
⋅ Preoccupation with the change in desire or arousal, particularly if it developed suddenly
⋅ Difficulty identifying an underlying cause for an acquired change
⋅ Reduced genital or non-genital sensations during sexual activity
⋅ Diminished physical arousal response despite adequate stimulation
⋅ Reduced excitement or pleasure during sexual activity
⋅ In some cases, physical discomfort that secondarily reduces interest
⋅ Reduced frequency of initiating sexual activity
⋅ Reduced responsiveness to a partner’s attempts to initiate
⋅ Avoidance of situations or cues that might otherwise prompt sexual interest
⋅ Withdrawal from physical intimacy more broadly, beyond sexual activity itself
Roughly 10% of women meet full diagnostic criteria, including the required distress, while a considerably larger proportion report low sexual desire without significant personal distress, an important distinction given the diagnosis’s specific requirement for distress.
Risk factors include relationship distress, depression and anxiety, significant life stress, certain medications (particularly SSRIs and hormonal contraceptives in some women), and major life transitions including new parenthood and menopause. Acquired presentations, developing after a period of previously typical desire and arousal, are often connected to one of these identifiable factors, while lifelong presentations may reflect a more longstanding pattern without a single clear trigger.
Comorbidity with depression and anxiety is substantial and frequently bidirectional, and relationship distress specifically shows a particularly strong, well-documented connection to this condition compared to some other sexual dysfunctions in this chapter.
FSIAD arises from an interaction of hormonal, psychological, relational, and pharmacological factors, often acting in combination rather than through a single identifiable cause.
Hormonal factors, particularly declining estrogen around menopause, and hormonal shifts during breastfeeding, are well-documented contributors to acquired difficulty, affecting both desire and the physical arousal response.
Psychological factors, including depression, anxiety, body image concerns, and difficulty being mentally present during sexual activity, are significant contributors, and the relationship between mood and desire is frequently bidirectional, low mood reduces desire, and reduced desire can itself contribute to distress and lowered mood.
Relationship factors carry particular weight for this specific condition; relationship distress, unresolved conflict, and a sense of emotional disconnection from a partner are strongly and consistently associated with reduced sexual interest and arousal, more so than for some of the other conditions covered in this chapter.
Medication effects, particularly SSRIs and, for some women, certain hormonal contraceptives, are recognized contributors to acquired difficulty.
Significant life stress and major transitions, including new parenthood, caregiving responsibilities, or other substantial life changes, frequently coincide with acquired difficulty, reflecting how sensitive sexual desire and arousal can be to broader life context and emotional bandwidth.
FSIAD is diagnosed when at least three of six specific symptoms are present: absent or reduced interest in sexual activity, absent or reduced sexual thoughts or fantasies, no or reduced initiation and unreceptive to a partner’s attempts to initiate, absent or reduced excitement or pleasure during activity on almost all occasions, absent or reduced response to internal or external erotic cues, or absent or reduced genital or non-genital sensations during activity. Symptoms must persist for a minimum of approximately six months and cause clinically significant distress. The clinician specifies lifelong or acquired, and generalized or situational.
The diagnosis requires that symptoms aren’t better explained by a non-sexual mental disorder, severe relationship distress, the effects of a substance or medication, or another medical condition, and crucially, aren’t solely accounted for by desire discrepancy alone, simply having lower desire than a partner, without personal distress, doesn’t meet criteria.
Differential diagnosis requires distinguishing genuine, distressing FSIAD from normal variation in sexual desire across individuals and across the lifespan, and from situations where reduced desire is a reasonable, undistressing response to relationship problems that would be better addressed through couples-focused intervention than a sexual dysfunction diagnosis specifically.
Treatment for FSIAD is tailored to the specific contributing factors identified, given the genuinely wide range of possible underlying causes.
Sex therapy and psychological approaches
Cognitive-behavioral and mindfulness-based approaches adapted for sexual concerns help address anxious self-monitoring, body image concerns, and difficulty being present during sexual activity, with mindfulness-based approaches in particular showing solid evidence for improving subjective arousal and desire.
Addressing relationship factors
Given the strong connection to relationship distress, couples therapy addressing underlying relational conflict or disconnection is often a central, sometimes essential, component of effective treatment.
Hormonal evaluation and treatment
For acquired difficulty connected to menopause, hormonal treatment, where appropriate and discussed with a physician, can meaningfully help, alongside other supportive approaches.
Flibanserin and bremelanotide
Two medications, flibanserin (a daily oral medication) and bremelanotide (an as-needed injectable), are specifically approved for low sexual desire in premenopausal women, working through different mechanisms affecting brain pathways involved in desire, though both carry specific considerations and side effects worth discussing carefully with a prescribing physician.
Addressing medication-related causes
When an SSRI or hormonal contraceptive is identified as contributing, reassessing this with the prescribing physician is an important consideration.
Consider whether the reduced desire is actually distressing you, or mainly reflects a discrepancy with a partner. If you’re genuinely comfortable with your level of desire, this distinction matters for what kind of help, if any, is actually useful.
If relationship tension feels connected to this, address that directly. Given how strongly relationship factors connect to this condition specifically, couples-focused conversation or therapy is often more directly helpful than treatments aimed purely at desire itself.
Talk to your physician about any medication you’re taking. SSRIs and some hormonal contraceptives are recognized contributors, and there are often reasonable alternatives worth discussing.
Be patient with yourself through major life transitions. New parenthood, menopause, and significant life stress all commonly affect desire, and this doesn’t necessarily reflect a lasting problem.
Seek a sex therapist for structured, evidence-based support. Mindfulness-based approaches in particular have solid evidence here and provide practical tools beyond simply talking through the difficulty.
The prognosis for FSIAD is generally good, particularly when relationship factors are directly addressed alongside any individual psychological or hormonal contributors.
Mindfulness-based sex therapy has accumulated solid evidence for meaningful improvement, and many women experience real benefit from approaches that reduce anxious self-monitoring and increase presence during sexual activity.
Acquired difficulty connected to a specific, identifiable factor, a medication, a life transition, menopause, tends to respond well once that factor is directly addressed. Comorbid depression, anxiety, or relationship distress generally requires concurrent attention for the most complete and durable improvement.
Seek evaluation if a persistent, significant reduction in sexual interest or arousal has lasted six months or more and is causing you genuine distress, not simply a difference from your partner’s level of desire.
Seek couples-focused support if relationship tension feels connected to the change, given how strongly this factor relates to this specific condition.
Seek evaluation if the change began after starting a new medication, particularly an SSRI or hormonal contraceptive, since this connection is well-recognized and worth discussing with your prescriber.
Someone in your life might be quietly looking for this. Share it:
These conditions share overlapping symptoms and are often misdiagnosed.
No. The diagnosis specifically requires significant personal distress connected to the reduced desire or arousal, not simply having lower desire than average or than a partner. Many women have a stable, lower level of sexual interest throughout their lives without this representing any disorder, particularly when it isn’t causing them distress.
Research has shown that for many women, desire and arousal aren’t as clearly sequential or separable as once assumed, desire doesn’t always precede arousal in a fixed order, and the two frequently overlap and influence each other. DSM-5 combined the earlier separate diagnoses of hypoactive sexual desire disorder and female sexual arousal disorder into one condition to better reflect this overlap.
Yes, relationship distress is one of the most strongly and consistently connected factors to this specific condition. When reduced desire is closely tied to relational conflict or disconnection, couples-focused therapy addressing the relationship directly is often more effective than approaches focused solely on desire itself.
Yes, flibanserin and bremelanotide are both specifically approved for low sexual desire in premenopausal women, working through different brain pathway mechanisms. Both have specific considerations and potential side effects worth discussing thoroughly with a prescribing physician alongside other treatment approaches like sex therapy.
Brotto, L. A., Atallah, S., Johnson-Agbakwu, C., Rosenbaum, T., Abdo, C., Byers, E. S., Graham, C., Nobre, P., & Wylie, K. (2016). Psychological and interpersonal dimensions of sexual function and dysfunction. Journal of Sexual Medicine, 13(4), 538–571. PubMed
Clayton, A. H., Goldstein, I., Kim, N. N., Althof, S. E., Faubion, S. S., Faught, B. M., Parish, S. J., Simon, J. A., Vignozzi, L., Christiansen, K., Davis, S. R., Freedman, M. A., Kingsberg, S. A., Kirana, P. S., Larkin, L., McCabe, M., & Sadovsky, R. (2018). The International Society for the Study of Women’s Sexual Health process of care for management of hypoactive sexual desire disorder in women. Mayo Clinic Proceedings, 93(4), 467–487. PubMed
Brotto, L. A., & Basson, R. (2014). Group mindfulness-based therapy significantly improves sexual desire in women. Behaviour Research and Therapy, 57, 43–54. PubMed
Brauer, M., van Leeuwen, M., Janssen, E., Newhouse, S. K., Heiman, J. R., & Laan, E. (2012). Attentional and affective processing of sexual stimuli in women with hypoactive sexual desire disorder. Archives of Sexual Behavior, 41(4), 891–905. PubMed
Parish, S. J., & Hahn, S. R. (2016). Hypoactive sexual desire disorder: a review of epidemiology, biopsychology, diagnosis, and treatment. Sexual Medicine Reviews, 4(2), 103–120. PubMed
